Seeking Alpha: AtriCure Is Successfully Using Marketing And Training To Drive Revenue

Small-cap cardiology med-tech AtriCure (NASDAQ:ATRC) did see its stock price momentum slow down from the 100%-plus pace between two of my prior pieces, but the better than 20% rise since late April of 2014 still isn't bad at all. This growth isn't just about the Street turning up a previously overlooked name; the company is delivering good beat-and-raise quarters and posting the sort of revenue growth that growth investors like to see from med-techs.

It looks as though growth is going to slow in the next year due to currency movements, but the underlying growth story at AtriCure remains intact. The company remains the only company with FDA-approved surgical ablation products and surgical ablation remain an underpenetrated option for treating a-fib and reducing stroke risk. Add in the potential of the AtriClip as another option in reducing stroke risk and management may not be overstating an annual blue-sky potential market of $1 billion a year. Against a market cap of less than $600 million, that argues that AtriCure's shares still have more to offer.

Continue reading here:
AtriCure Is Successfully Using Marketing And Training To Drive Revenue